for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gilead Sciences, Inc.

GILD.OQ

Latest Trade

62.25USD

Change

0.00(0.00%)

Volume

2,349,615

Today's Range

61.77

 - 

62.50

52 Week Range

60.90

 - 

85.97

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
62.25
Open
62.10
Volume
2,349,615
3M AVG Volume
183.75
Today's High
62.50
Today's Low
61.77
52 Week High
85.97
52 Week Low
60.90
Shares Out (MIL)
1,253.72
Market Cap (MIL)
78,044.34
Forward P/E
8.89
Dividend (Yield %)
4.37

Next Event

Q3 2020 Gilead Sciences Inc Earnings Release

Latest Developments

More

Jyseleca® (Filgotinib) Approved In Japan For Rheumatoid Arthritis

Gilead Sciences Prices $7.25 Bln Of Senior Unsecured Notes

Gilead Sciences Files Preliminary Prospectus Supplement Related To Potential 6-Part Notes Offering

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Industry

Biotechnology & Drugs

Contact Info

333 LAKESIDE DR

FOSTER CITY, CA

94404

United States

+1.650.5743000

https://www.gilead.com/

Executive Leadership

Daniel O'Day

Chairman of the Board, Chief Executive Officer

Andrew D. Dickinson

Chief Financial Officer, Executive Vice President

Brett Alan Pletcher

Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary

Jyoti Mehra

Executive Vice President of Human Resources

Linda Higgins

Senior Vice President - Head of External Innovation

Key Stats

2.48 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

26.1K

2018

22.1K

2019

22.4K

2020(E)

24.2K
EPS (USD)

2017

8.840

2018

6.670

2019

6.630

2020(E)

7.001
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.52
Price To Book (MRQ)
4.33
Price To Cash Flow (TTM)
70.37
Total Debt To Equity (MRQ)
133.70
LT Debt To Equity (MRQ)
117.06
Return on Investment (TTM)
-0.58
Return on Equity (TTM)
-0.48

Latest News

Latest News

Gilead to pay $97 million to settle U.S. kickback probe

Gilead Sciences Inc has agreed to pay $97 million to resolve U.S. government claims it used a purportedly independent charity to pay illegal kickbacks to cover Medicare patients' out-of-pocket costs for its pulmonary arterial hypertension drug Letairis.

Gilead to pay $97 million to resolve kickback claims -U.S. Justice Department

Gilead Sciences Inc has agreed to pay $97 million to resolve claims that it illegally used a foundation as a conduit to pay the copays of thousands of Medicare patients taking Gilead's pulmonary arterial hypertension drug Letairis, the Justice Department said on Wednesday...

BRIEF-Canada has signed agreement with Sanofi for up to 72 million doses Of potential COVID-19 vaccine - minister

* CANADA HAS SIGNED AN AGREEMENT FOR AN EXTRA 14 MILLION DOSES OF POTENTIAL MODERNA COVID-19 VACCINE

Immunomedics' cancer drug helps reduce tumor size in early-stage study

Immunomedics, Inc said on Friday its treatment, Trodelvy, helped partially reduce tumor size in an early-stage study testing it in brain cancer patients.

Immunomedics reports promising early-stage data from cancer drug study

Immunomedics, Inc said on Friday its treatment, Trodelvy, helped partially reduce tumor size in an early-stage study testing it in brain cancer patients.

Gilead bolsters cancer portfolio with $21 billion acquisition of Immunomedics

Gilead Sciences Inc will acquire biotech company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two companies said in a joint statement on Sunday.

Eli Lilly's drug cuts COVID-19 recovery time in remdesivir-combo study

Eli Lilly and Co said on Monday its rheumatoid arthritis drug shortened the time to recovery in hospitalized COVID-19 patients when used along with Gilead Sciences Inc's remdesivir.

Gilead's shares rise after $21 billion deal for Immunomedics

Shares of Gilead Sciences Inc <GILD.O> rose 3.2% on Monday, reversing their premarket losses as investors shrugged off concerns over the steep premium the U.S. drugmaker was willing to pay for Immunomedics Inc <IMMU.O>.

Gilead's shares fall on concerns over high premium cancer deal

Shares of Gilead Sciences Inc fell nearly 2% on Monday as investors questioned the steep premium the U.S. drugmaker was willing to pay for Immunomedics Inc.

Eli Lilly's rheumatoid arthritis drug helps recovery in COVID-19 patients

Eli Lilly and Co said on Monday its rheumatoid arthritis drug Olumiant helped reduce the time taken to recover from COVID-19 in hospitalized patients in a clinical trial.

CORRECTED-UPDATE 2-Gilead to buy cancer drugmaker Immunomedics for $21 bln

Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two companies said in a joint statement on Sunday.

Gilead nears deal to buy Immunomedics for more than $20 billion - WSJ

Gilead Sciences Inc <GILD.O> is nearing a deal to buy biopharmaceutical company Immunomedics Inc <IMMU.O> for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday.

Gilead nears deal to buy Immunomedics for more than $20 bln -WSJ

Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

Exclusive: U.S. hospitals turn down remdesivir, limit use to sickest COVID-19 patients

U.S. hospitals have turned down about a third of their allocated supplies of the COVID-19 drug remdesivir since July as need for the costly antiviral wanes, the Department of Health and Human Services (HHS) confirmed on Friday.

EXCLUSIVE-U.S. hospitals turn down remdesivir supplies, limit use to sickest COVID-19 patients

U.S. hospitals have turned down about a third of their allocated supplies of the COVID-19 drug remdesivir since July as need for the costly antiviral wanes, according to unpublished government statistics provided to Reuters by a U.S. pharmacists' group.

Special Report: Big Pharma wages stealth war on drug price watchdog

As evidence grew this spring that the drug remdesivir was helping COVID-19 patients, some Wall Street investors bet on analysts’ estimates that its maker, Gilead Sciences Inc, could charge up to $10,000 for the treatment.

FDA expands emergency use of Gilead's remdesivir in hospitalized COVID-19 patients

Gilead Inc <GILD.O> said on Friday the U.S. Food and Drug Administration expanded the emergency use authorization of its experimental antiviral COVID-19 treatment, remdesivir, to allow its use in all hospitalized COVID-19 patients.

Gilead: FDA could expand remdesivir use despite mixed data

The U.S. Food and Drug Administration could update its emergency use authorization for Gilead Sciences Inc's <GILD.O> drug remdesivir to include patients hospitalized with moderate COVID-19, despite mixed trial results, the company's top research executive said on Friday.

Gilead study: remdesivir has marginal benefit for moderate COVID patients

Moderately ill COVID-19 patients saw their condition improve after a 5-day course of Gilead Sciences Inc's remdesivir, but a 10-day course did not show a benefit and the drug did not significantly shorten hospital stays, according to new data.

Gilead shares slide after FDA knocks back rheumatoid arthritis drug

Shares of Gilead Sciences <GILD.O> fell 3% after the U.S. Food and Drug Administration declined to approve its experimental rheumatoid arthritis treatment, a major setback for one of the drugmaker's important products.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up